Keyword: Johnson & Johnson
Despite uncertainty heading into 2017, most drug stocks escaped the stagnation of 2016—some far more than others.
Here's some other vaccine news of note for the week.
Amid a particularly severe flu season, FDA chief Scott Gottlieb said the "holy grail" of vaccines—a shot that fights any strain of virus—is years off.
Johnson & Johnson is trumpeting more Invokana outcomes data to support its approval to reduce cardiovascular risks.
When it comes to real-world heart benefits, SGLT2 diabetes drugs continue to impress—this time with reduced risks of heart attack and stroke.
With a new study in patients with peripheral artery disease, Johnson & Johnson has once again bolstered its case for another Xarelto approval.
A judge has ordered 1,200 Xarelto liability cases against J&J and Bayer to be prepared for trial in courts around the country.
J&J paid out $15 billion in rebates and discounts in 2017 as its average selling price slipped 4.6%.
Drugmakers haven't been able to reach a settlement with the cities and counties suing them over the opioid epidemic.
Lilly and BI are gunning for a heart-failure nod for Jardiance. And they want to be able to talk up the drug’s effects on exercise ability, too.